The Value of Endorectal MRI in the Early Diagnosis of Prostate Cancer

Comet-Batlle, Josep; Vilanova, Joan C.; Saladié-Roig, José-Maria; Gelabert-Más, Antoni; Barceló‐Vidal, C.

doi:10.1016/s0302-2838(03)00248-3

Cited by 33 publications

(21 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings were nearly consistent with the studies conducted by Adilson et al .,[10] Yasushi et al .,[11] and Delphine et al . [12] In our study, out of 87 patients, MR-spectroscopy showed choline-cretine peak in 74 patients and normal citrate peak in 13 patients. In our study, 9 (10.3%) patients had a choline-cretine/citrate ratio score of 1 (normal).…”

Section: Discussionsupporting

confidence: 50%

Endorectal coil MRI and MR-spectroscopic imaging in patients with elevated serum prostate specific antigen with negative trus transrectal ultrasound guided biopsy

et al. 2013

View full text Add to dashboard Cite

Background:The aim of this study was to see the efficacy of endorectal coil MRI and MR spectroscopic imaging in patients with elevated serum PSA and negative transrectal ultrasonography (TRUS)-guided biopsy.Materials and Methods:This study was conducted on 87 patients presented with: • Elevated prostatic specific antigen levels >5 ng/ml • Symptoms and signs of prostatic carcinoma • Patients with negative TRUS-guided biopsy • Suspicious lesion on TRU. All the patients were subjected to TRUS and followed by TRUS-guided biopsy of the lesion identified on endorectal coil MRI and MR-Spectroscopy. TRUS-guided biopsy of prostate was done with a Siemens Sonoline Adana Scanner. The scanning was performed by mechanical probe 5-7.5 MHz.Results:Out of 87 patients, 43 (49.4%) had hypointense lesion, 11 (12.6%) had hyperintense lesion. Out of 87 patients, MR-spectroscopy showed peak choline-creatine in 74 patients. Normal citrate peak was seen in 13 patients. Patients who had choline-creatine peak, among them 28 (37.8%) had peak in left peripheral zone, 23 (31.1%) had peak in the right peripheral zone, 2 (2.7%) had peak in the central zone, 17 had (23%) peak bilaterally. Four patients (5.4%) had peaks in right and central zones. The difference was statistically significant (P < 0.001).Conclusion:Prostatic biopsy directed with endorectal coil MRI and MR-spectroscopic imaging findings in patients with elevated serum PSA and prior negative biopsy, improves the early diagnosis of prostatic carcinoma and accurate localization of prostate cancer within the gland.

show abstract

Section: Discussionsupporting

confidence: 50%

Endorectal coil MRI and MR-spectroscopic imaging in patients with elevated serum prostate specific antigen with negative trus transrectal ultrasound guided biopsy

et al. 2013

View full text Add to dashboard Cite

show abstract

“…He performed a 6-core PB based on the findings and reported a 28% of PCa. Comet-Battle et al 25 had similar results, with a sensitivity of 80% and specificity of 76% using sextant PB for correlation. Beyersdorff et al 26 exhibited that T2-weighed e-MRI has increased diagnostic performance with a sensitivity of 83%.…”

Section: Discussionmentioning

confidence: 74%

Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate

Engelhard

Zugor

et al. 2009

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The purpose of this study is to report our method in detecting prostate cancer (PCa) using an 18-core transrectal ultrasound (TRUS) prostate biopsy (PB) schema, in combination with additional targeted cores from suspicious images in conventional (e-cMRI) and functional (e-fMRI) endorectal magnetic resonance imaging (e-MRI) of the prostate. From 2004 to 2008, 260 consecutive patients with a clinical suspicion of PCa underwent PB and were prospectively studied. e-cMRI and e-fMRI was performed in all patients before PB. The patients were divided into two groups (A and B) according to the results of their radiological findings (group A ¼ suspicious findings, group B ¼ non-suspicious findings). After the images were processed, an 18-core TRUS-guided PB was performed. When a patient exhibited a suspicious site on e-cMRI and e-fMRI images, three additional targeted PBs were obtained from that site. In group A, 17.5% of PCa was detected by the 18-core PB and 56.5% of PCa was detected by the targeted cores. The overall PCa detection rate (18 þ targeted cores) was 73.9%. The overall specificity was 73.9%. In group B, overall false-positive detection rate reached 19.2%, with the overall sensitivity being 80.8%. The method described above is not only practical but also a promising modality in PCa detection. As seen, PCa was optimally detected when combining the 18-core and targeted-core PB schema together. Non-suspicious images do not rule out the probability of PCa, thus justifying a PB in these patients as well.

show abstract

“…Moreover, in retrospective site-by-site analysis, MRI results did not correlate significantly with individual biopsy site findings (p = 0.126); sensitivity was 65% and PPV was 12% [9] . In another study, Comet-Batlle et al [10] [86] , six studies with a total of 215 patients were examined to assess the efficacy of MRI for targeting cancer when compared to biopsies in patients with previous negative prostate biopsies and persistently elevated PSA levels. The cancer detection rate at re-biopsy was 21-40%.…”

Section: Role Of Mri After Previous Negative Biopsymentioning

confidence: 99%

Imaging in Prostate Cancer Diagnosis: Present Role and Future Perspectives

et al. 2011

View full text Add to dashboard Cite

Prostate cancer (PCa) remains a major health concern for the male population. Detection and primary diagnosis of PCa are based on digital rectal examination, serum prostate-specific antigen levels, and transrectal ultrasound (TRUS)-guided random biopsy. Moreover, the gold standard for detecting PCa, systematic biopsy, lacks sensitivity as well as grading accuracy. This review summarizes recent developments of ultrasonography modalities and functional magnetic resonance imaging (MRI) in the diagnosis of PCa. A comparison between the different methods is presented, including their clinical value and usefulness. It is concluded that innovative ultrasound techniques (including ultrasound contrast agents, 3-D and 4-D sonography, elastography and harmonic sonography) promise benefits in comparison to standard TRUS to accurately diagnose PCa. Promising advances have been made in the detection of PCa with multiparametric MRI. The combination of conventional and functional MRI techniques (including diffusion-weighted imaging, dynamic contrast-enhanced MRI, and MR spectroscopy) can provide information for differentiating PCa from noncancerous tissue and can be used for MRI-guided biopsies, especially in patients with persistent elevation of serum prostate-specific antigen and previous negative TRUS-guided biopsies. However, functional MRI technique and MRI-guided biopsy remain expensive and complex tools presenting inherent challenges.

show abstract

The Value of Endorectal MRI in the Early Diagnosis of Prostate Cancer

Cited by 33 publications

References 24 publications

Endorectal coil MRI and MR-spectroscopic imaging in patients with elevated serum prostate specific antigen with negative trus transrectal ultrasound guided biopsy

Endorectal coil MRI and MR-spectroscopic imaging in patients with elevated serum prostate specific antigen with negative trus transrectal ultrasound guided biopsy

Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate

Imaging in Prostate Cancer Diagnosis: Present Role and Future Perspectives

Contact Info

Product

Resources

About